Research study · Gut Microbes Reports · 2026
Oleoylethanolamide supplementation enriches Akkermansia muciniphila and modulates intestinal barrier function in adults with obesity: A randomized, double-blind, placebo-controlled trial
Verified on PubMed Oxford CEBM Level 1B: Randomized Controlled Trial
A 2026 randomized controlled trial in Gut Microbes Reports tested oleoylethanolamide in obesity. It made no clear difference to the gut's overall bacterial community. This study shows that this supplement was tolerated over three months and that it may nudge a few gut bacteria and inflammation markers, but it does not establish any real health.
In plain language
Study overview
Researchers in Australia studied 57 adults with obesity. Half took a supplement containing a natural fat-derived compound, and half took a harmless filler capsule, for three months, with neither the participants nor the researchers knowing who got which.
Findings
It made no clear difference to the gut's overall bacterial community. Some specific gut bacteria and a few inflammation and gut-lining markers shifted in the supplement group, but these were small, mostly unconfirmed by the full statistical comparison, and many measurements showed no change.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
In this randomized, double-blind, placebo-controlled trial, 57 adults with obesity (BMI 30–40 kg/m²) received either 300 mg of TRPTI, providing 250 mg/day of OEA (n = 28), or placebo (n = 29) for 12 weeks. Outcomes included shotgun metagenomics, microbiome profiling, intestinal barrier and inflammatory biomarkers, and safety measures. OEA was safe and well-tolerated with no adverse changes in clinical biomarkers. Although overall microbial diversity remained stable, OEA induced selective, health-relevant compositional shifts. Notably, Faecalibacterium prausnitzii and Akkermansia muciniphila were enriched. These changes coincided with increased occludin at Week 12 and interleukin-2 at Week 6, while reducing interleukin-1β, consistent with improved epithelial barrier dynamics and reduced inflammation. Functional pathway analysis suggested enhanced microbial metabolic and redox capacity. The authors conclude OEA selectively enriches beneficial gut bacteria without disrupting microbiome stability and position it as a safe, targeted microbiome-modulating ingredient.
The paper
Citation
Batacan R, Rao A, Bajagai YS, Stanley D, Briskey D Oleoylethanolamide supplementation enriches Akkermansia muciniphila and modulates intestinal barrier function in adults with obesity: A randomized, double-blind, placebo-controlled trial. Gut Microbes Reports (2026). PubMed 41924306 · DOI
Read the abstract as published
Targeted modulation of the gut microbiome represents a promising nutritional strategy to support metabolic and intestinal health in overweight and obese adults. Oleoylethanolamide (OEA) is an endogenous lipid mediator that regulates satiety, lipid metabolism, and inflammation, but its effects on the human microbiome are not well defined. In this randomized, double-blind, placebo-controlled trial, 57 adults with obesity (BMI 30-40 kg/m²) received either 300 mg of TRPTI, providing 250 mg/day of OEA (n = 28), or placebo (n = 29) for 12 weeks. Outcomes included shotgun metagenomics, microbiome profiling, intestinal barrier and inflammatory biomarkers, and safety measures. OEA was safe and well-tolerated with no adverse changes in clinical biomarkers. Although overall microbial diversity remained stable, OEA induced selective, health-relevant compositional shifts. Notably, Faecalibacterium prausnitzii and Akkermansia muciniphila were enriched. These changes coincided with functional host benefits, including increased occludin at Week 12 and interleukin-2 at Week 6, while reducing interleukin-1β, consistent with improved epithelial barrier dynamics and reduced inflammation. Functional pathway analysis suggested enhanced microbial metabolic and redox capacity. These findings indicate OEA supplementation selectively enriches beneficial gut bacteria - particularly A. muciniphila, while improving gut barrier biomarkers and immune function without disrupting microbiome stability. These findings position OEA as a safe, targeted microbiome-modulating ingredient with potential applications for supporting gut and metabolic health.
Abstract text as indexed by PubMed for this identifier.
Limitations the authors noted
Only 44 of 57 participants completed the study (about 23% attrition), and per-group analysed numbers are small (22 per arm in demographics). Primary microbiome comparison showed no significant overall between-group difference; key taxa findings rely on exploratory and within-group analyses without FDR-significant between-group results for F. prausnitzii. Multiple biomarkers and taxa tested with several reported at p < 0.05 without consistent correction across the biomarker panel. Circulating occludin does not directly measure intestinal permeability; authors state direct assessment is needed. OEA plasma and fecal concentrations were not measured; no correlation or mediation analysis performed. Functional pathway findings did not survive FDR correction and are described as speculative. Sponsor-funded by Gencor Pacific, and several authors are associated with RDC Clinical and LipiSperse de
In practice
Why this matters
This study shows that this supplement was tolerated over three months and that it may nudge a few gut bacteria and inflammation markers, but it does not establish any real health benefit, weight loss, or change in gut function. The trial was small, many participants dropped out, the company that made the product paid for the study, and the effects that did appear need confirmation in larger, longer studies that also measure the gut lining directly and test other doses.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding cannabinoids and Obesity?
It made no clear difference to the gut's overall bacterial community. Some specific gut bacteria and a few inflammation and gut-lining markers shifted in the supplement group, but these were small, mostly unconfirmed by the full statistical comparison, and many measurements showed no change.
What study limitations or clinical safeguards should patients keep in mind?
Only 44 of 57 participants completed the study (about 23% attrition), and per-group analysed numbers are small (22 per arm in demographics). Primary microbiome comparison showed no significant overall between-group difference; key taxa findings rely on exploratory and within-group analyses...
Browse related research
Condition: Inflammation Condition: Obesity Topic: Oleoylethanolamide
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 19, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
